
Drug Cost Implications Highlight SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
Pharmacy benefit manager study indicates that moving patients with hemophilia from standard half-life to extended half-life coagulation factor products carries a significant cost increase.
Pharmacy benefit manager reports specialty drugs drive 97% of spending for hereditary angioedema care.
Spending on specialty medications is rapidly approaching half of overall medicine spending from a small volume of prescriptions filled.
New treatments for cystic fibrosis, migraines, and multiple sclerosis expected to help push specialty drug costs on the pharmacy benefit to nearly 50% of total drug spending by 2020.
Study finds improving adherence to disease-modifying multiple sclerosis medications could reduce clinical relapses while saving on medical costs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.